Braveheart Bio, Inc.

Healthcare · Biotechnology · United States

Last price 21.19 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.73B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.